Capsugel investing in enhanced micronisation capacity and capabilities

Investment further strengthens pilot-scale and commercial manufacturing capabilities 

Capsugel, a global manufactuer in dosage forms and solutions, today announced an expansion of its facility in Quakertown Pennsylvania, to meet increasing customer demand for its micronisation services for both clinical and commercial manufacturing. The company will double the size of its current pilot-scale capacity for clinical trial quantities and increase the number of suites dedicated to commercial manufacturing. 

Micronisation of active pharmaceutical ingredients is accomplished using proprietary jet milling equipment. The Quakertown facility operates as a full-service provider of particle-size reduction and particle-size control/classification technologies for pharmaceutical customers. The acquisition expanded the company’s suite of bioavailability enhancement tools aimed at improving the bioavailability of APIs with either dissolution or solubility challenges.

“Our customers are increasingly seeking specialized partners in early-stage compound assessments and product design, with poor dissolution and/or solubility often being at the forefront of their challenges,” said Amit Patel, Sr. Vice President, Capsugel. “Micronisation and nano-milling technology is a significant component of Capsugel’s overall service offering, and this investment further strengthens our ability to rapidly advance challenging compounds to clinic and ultimately commercialisation.” 

In addition to enabling increased capacity, the added suites will feature new, single-use containment technologies to accommodate continued growth in potent and highly potent compounds. The new equipment and suites are scheduled to be operational by January 2017.

“One of the many reasons we were eager to join Capsugel was the opportunity to become a part of its unique design, development and manufacturing offering,” said Wayne Sigler, president of Powdersize, a division of Capsugel. “This investment further supports the role of micronisation and sub-micronisation in compound assessments and product design through commercialisation, bringing more benefits to our customers.”